TABLE 3.

HPV Prevalence Among All Unvaccinated Participants (N = 899), by Body Site and Gender Identity

	TGW		MSM
	n	%	n	%	PR (95% CI)
Any site
Any HPV*	43	97.7	691	80.8	1.2 (1.1–1.3)
Vaccine type/s†	40	90.9	547	64.0	1.4 (1.3–1.6)
Anal
Any HPV*	39	88.6	606	70.9	1.3 (1.1–1.4)
Vaccine type/s†‡	22	50.0	311	36.4	1.4 (1.0–1.9)
Oral
Any HPV*	4	9.1	81	9.5	1.0 (0.4–2.5)
Vaccine type/s†	1	2.3	26	3.0	0.7 (0.1–5.4)
Serum
Vaccine type/s†	37	84.1	467	54.6	1.5 (1.3–1.8)
Naïve‡
Naïve to ≥1 vaccine type†‡	29	65.9	775	90.6	0.7 (0.6–0.9)
Naïve to HPV type 16‡	16	36.4	580	67.8	0.5 (0.4–0.8)

^*Any of 37 HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39).

^†At least 1 quadrivalent vaccine type (HPV 6, 11, 16, 18).

^‡Participants were considered naïve if they had no anal, oral, or serologic evidence of infection with that HPV type.

Bold indicates significance.

TGW indicates transgender women; MSM, men who have sex with men.